Provided by Tiger Trade Technology Pte. Ltd.

Oculis

28.68
+0.13500.47%
Volume:206.70K
Turnover:5.94M
Market Cap:1.64B
PE:-10.52
High:28.90
Open:28.53
Low:28.52
Close:28.54
52wk High:29.36
52wk Low:14.00
Shares:57.07M
Float Shares:46.06M
Volume Ratio:1.02
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7247
EPS(LYR):-2.3426
ROE:-92.19%
ROA:-33.35%
PB:9.62
PE(LYR):-12.24

Loading ...

Company Profile

Company Name:
Oculis
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
49
Office Location:
Bahnhofstrasse 20,Zug,Zug,Switzerland
Zip Code:
6300
Fax:
- -
Introduction:
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.